

PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY

Buscopan® Compositum



Spasmolytic and Analgesic

Active Constituents

Hyoscine-N-Butylbromide 4 mg/mL
Dipyrone 500 mg/mL

Description

Buscopan® compositum is a combination of the spasmolytic agent Buscopan® (Hyoscine-N-Butylbromide) and the analgesic dipyrone.

Activity

Buscopan® compositum acts in three ways:

- directly as a spasmolytic
- directly as an analgesic
- indirectly as an anti-inflammatory agent

These three actions are interrelated.

Pharmacology

Buscopan® blocks the transmission of neural stimuli at the intramural ganglia of the hollow abdominal organs, which are innervated by the parasympathetic nervous system.

Absorption and distribution studies established that Buscopan® compositum is concentrated in the walls of the hollow abdominal organs causing a spasmolysis. This accounts for the lack of systemic atropine like side-effects. Buscopan® remains mainly in the enterohepatic circulation. Dipyrone has central analgesic activity plus a direct effect on the smooth muscle

cells, lowering the excitability of the smooth muscle fibres.

This latter effect together with dipyrone's anti-inflammatory action, enhances the properties of Buscopan®. Dipyrone is well tolerated parenterally.

Clinical Action

Buscopan® compositum is recommended in all conditions of severe pain involving spasm in the gastrointestinal, biliary and urogenital tracts. With intravenous administration pain often recedes before the injection is completed and pain relief is clearly apparent. The injection may be repeated after four hours if necessary. The duration of action is approximately six hours.

Buscopan® compositum brings about relief of colic by abolishing the spasm and relieving the pain ensuring a rapid return to normal peristalsis and intestinal function.

Enteritis associated with scouring quickly debilitates the animal through excessive fluid loss. Buscopan® compositum normalises intestinal tone and function, preventing further fluid loss. Concurrent treatment with an appropriate antibacterial or anthelmintic may be instituted. Clinical reports confirm Buscopan® compositum's usefulness of colic in horses and gastroenteritis in small animals.

Indications

Assists in the treatment of gastro-enteritis.

Spasm of the gastro-intestinal, biliary or urogenital tracts associated with severe pain.

Buscopan® compositum relieves both pain and smooth muscle spasm.

Horses/Foals

Spasmodic colic, scours, oesophageal obstruction, enteritis with diarrhoea.

Dogs

Colic, gastro-enteritis with diarrhoea, vomiting, spasm of the urogenital tract, pain associated with digestive disturbances, tenesmus, urinary calculi.

In gastro-enteritis Buscopan® compositum can be used in combination with antibiotics, sulphonamides or anthelmintics, as required.

Directions for use

Horses: 20–30 mL intravenously.

Foals: 5–10 mL intravenously.

Dogs: 1–2.5 mL subcutaneously or intravenously.

**MEAT WITHHOLDING PERIOD
HORSES - DO NOT ADMINISTER
LATER THAN 28 DAYS BEFORE
SLAUGHTER FOR HUMAN CON-
SUMPTION.**

Disposal

Dispose of empty container by wrapping with paper and putting in garbage.

Presentation

100 mL bottle, solution for injection.

Storage

Store below 30° C (Room Temperature). Protect from light.

After opening, the colour of the injection solution may change. This does not influence efficacy.

Distributed by
Boehringer Ingelheim Pty Limited
Animal Health Division
Level 1
78 Waterloo Road
NORTH RYDE N.S.W. 2113
NRA 53006/0600